PCIDB

KNApSAcK Metabolite C00001352

Index

Metabolite

Species

Human Protein
/ Gene in interactions

Related Diseases

Metabolite

KNApSAcK Entry

id	C00001352
Name	L-Cystine
CAS RN	56-89-3
Standard InChI	InChI=1S/C6H12N2O4S2/c7-3(5(9)10)1-13-14-2-4(8)6(11)12/h3-4H,1-2,7-8H2,(H,9,10)(H,11,12)/t3-,4-/m0/s1
Standard InChI (Main Layer)	InChI=1S/C6H12N2O4S2/c7-3(5(9)10)1-13-14-2-4(8)6(11)12/h3-4H,1-2,7-8H2,(H,9,10)(H,11,12)

Cluster

Phytochemical cluster
KCF-S cluster	No. 8345

Link

ChEMBL

By standard InChI	CHEMBL590540
By standard InChI Main Layer	CHEMBL366563 CHEMBL590540

KEGG

By LinkDB	C00491

CTD

By CAS RN	D003553

Species

Summary

Plant class

class name	count

Family

family name	count

List (1)

* NCBI

KNApSAcK organism	*ID	*family	*plant class	*kingdom

Human Protein / Gene in interaction

3 ChEMBL Protein in interactions

accession	description	class description	compound	assay ID (# of activities)	# of diseases (OMIM / KEGG)
Q9UBT6	DNA polymerase kappa	Enzyme	CHEMBL590540	CHEMBL1794536 (1)	0 / 0
O00255	Menin	Unclassified protein	CHEMBL590540	CHEMBL1614257 (1)	2 / 5
Q03164	Histone-lysine N-methyltransferase 2A	Enzyme	CHEMBL590540	CHEMBL1614257 (1)	1 / 3

CTD interaction (10)

compound	gene	gene name	gene description	interaction	interaction type	form	reference pmid
D003553	883	CCBL1 GTK KAT1 KATI	cysteine conjugate-beta lyase, cytoplasmic (EC:2.6.1.64 2.6.1.7 4.4.1.13)	CCBL1 protein results in increased amination of Cystine	increases amination	protein	22093698
D003553	6519	SLC3A1 ATR1 CSNU1 D2H NBAT RBAT	solute carrier family 3 (amino acid transporter heavy chain), member 1	[SLC3A1 protein co-treated with SLC7A9 protein] results in increased uptake of Cystine	affects cotreatment / increases uptake	protein	14978168
D003553	6519	SLC3A1 ATR1 CSNU1 D2H NBAT RBAT	solute carrier family 3 (amino acid transporter heavy chain), member 1	SLC3A1 protein results in increased uptake of Cystine	increases uptake	protein	18845132
D003553	6520	SLC3A2 4F2 4F2HC 4T2HC CD98 CD98HC MDU1 NACAE	solute carrier family 3 (amino acid transporter heavy chain), member 2	[Bilirubin results in increased activity of [SLC7A11 protein co-treated with SLC3A2 protein]] which results in increased uptake of Cystine	affects cotreatment / increases activity / increases uptake	protein	22216172
D003553	6520	SLC3A2 4F2 4F2HC 4T2HC CD98 CD98HC MDU1 NACAE	solute carrier family 3 (amino acid transporter heavy chain), member 2	[[Bilirubin results in increased activity of [SLC7A11 protein co-treated with SLC3A2 protein]] which results in increased uptake of Cystine] which results in increased abundance of Glutathione	affects cotreatment / increases abundance / increases activity / increases uptake	protein	22216172
D003553	6520	SLC3A2 4F2 4F2HC 4T2HC CD98 CD98HC MDU1 NACAE	solute carrier family 3 (amino acid transporter heavy chain), member 2	[[[Bilirubin results in increased activity of [SLC7A11 protein co-treated with SLC3A2 protein]] which results in increased uptake of Cystine] which results in increased abundance of Glutathione] which results in decreased susceptibility to Hydrogen Peroxide	affects cotreatment / decreases response to substance / increases abundance / increases activity / increases uptake	protein	22216172
D003553	23657	SLC7A11 CCBR1 xCT	solute carrier family 7 (anionic amino acid transporter light chain, xc- system), member 11	[Bilirubin results in increased activity of [SLC7A11 protein co-treated with SLC3A2 protein]] which results in increased uptake of Cystine	affects cotreatment / increases activity / increases uptake	protein	22216172
D003553	23657	SLC7A11 CCBR1 xCT	solute carrier family 7 (anionic amino acid transporter light chain, xc- system), member 11	[[Bilirubin results in increased activity of [SLC7A11 protein co-treated with SLC3A2 protein]] which results in increased uptake of Cystine] which results in increased abundance of Glutathione	affects cotreatment / increases abundance / increases activity / increases uptake	protein	22216172
D003553	23657	SLC7A11 CCBR1 xCT	solute carrier family 7 (anionic amino acid transporter light chain, xc- system), member 11	[[[Bilirubin results in increased activity of [SLC7A11 protein co-treated with SLC3A2 protein]] which results in increased uptake of Cystine] which results in increased abundance of Glutathione] which results in decreased susceptibility to Hydrogen Peroxide	affects cotreatment / decreases response to substance / increases abundance / increases activity / increases uptake	protein	22216172
D003553	11136	SLC7A9 BAT1 CSNU3	solute carrier family 7 (amino acid transporter light chain, bo,+ system), member 9	[SLC3A1 protein co-treated with SLC7A9 protein] results in increased uptake of Cystine	affects cotreatment / increases uptake	protein	14978168

Related Disease

Diseases related to proteins in ChEMBL interactions

OMIM (3)

OMIM	preferred title	UniProt
#605130	Hairy elbows, short stature, facial dysmorphism, and developmental delay	Q03164
#145000	Hyperparathyroidism 1; hrpt1	O00255
#131100	Multiple endocrine neoplasia, type i; men1	O00255

KEGG DISEASE (7)

KEGG	disease name	UniProt
H00033	Adrenal carcinoma	O00255 (related)
H00034	Carcinoid	O00255 (related)
H00045	Malignant islet cell carcinoma	O00255 (related)
H00246	Primary hyperparathyroidism	O00255 (related)
H01102	Pituitary adenomas	O00255 (related)
H00001	Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)	Q03164 (related) Q03164 (marker)
H00002	Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia)	Q03164 (related)

Diseases related to CTD interactions

2 disease from interactions of metabolites

MeSH disease	OMIM	compound	disease name	evidence type	reference pmid
D056486		D003553	Drug-Induced Liver Injury	marker/mechanism	22230336
D012480		D003553	Salmonella Infections	therapeutic	19374741